HOOKIPA Pharma Inc. (HOOK)
HOOKIPA Pharma Statistics
Share Statistics
HOOKIPA Pharma has 9.66M shares outstanding. The number of shares has increased by -88.16% in one year.
Shares Outstanding | 9.66M |
Shares Change (YoY) | -88.16% |
Shares Change (QoQ) | -71.31% |
Owned by Institutions (%) | 4.4% |
Shares Floating | 6.88M |
Failed to Deliver (FTD) Shares | 10.54K |
FTD / Avg. Volume | 8.41% |
Short Selling Information
The latest short interest is 36.24K, so 0.38% of the outstanding shares have been sold short.
Short Interest | 36.24K |
Short % of Shares Out | 0.38% |
Short % of Float | 0.5% |
Short Ratio (days to cover) | 1.08 |
Valuation Ratios
The PE ratio is -0.94 and the forward PE ratio is -0.87. HOOKIPA Pharma's PEG ratio is 0.07.
PE Ratio | -0.94 |
Forward PE | -0.87 |
PS Ratio | 3.8 |
Forward PS | 0.1 |
PB Ratio | 0.85 |
P/FCF Ratio | -1.24 |
PEG Ratio | 0.07 |
Enterprise Valuation
HOOKIPA Pharma Inc. has an Enterprise Value (EV) of -33.97M.
EV / Earnings | 0.42 |
EV / Sales | -1.69 |
EV / EBITDA | 0.44 |
EV / EBIT | 0.35 |
EV / FCF | 0.55 |
Financial Position
The company has a current ratio of 3.5, with a Debt / Equity ratio of 0.07.
Current Ratio | 3.5 |
Quick Ratio | 3.5 |
Debt / Equity | 0.07 |
Total Debt / Capitalization | 6.8 |
Cash Flow / Debt | -8.77 |
Interest Coverage | -308.18 |
Financial Efficiency
Return on equity (ROE) is -0.91% and return on capital (ROIC) is -101.78%.
Return on Equity (ROE) | -0.91% |
Return on Assets (ROA) | -0.51% |
Return on Capital (ROIC) | -101.78% |
Revenue Per Employee | 133.3K |
Profits Per Employee | -540.26K |
Employee Count | 151 |
Asset Turnover | 0.12 |
Inventory Turnover | n/a |
Taxes
Income Tax | 368K |
Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -80.26% in the last 52 weeks. The beta is 0.7, so HOOKIPA Pharma's price volatility has been higher than the market average.
Beta | 0.7 |
52-Week Price Change | -80.26% |
50-Day Moving Average | 1.9 |
200-Day Moving Average | 4.32 |
Relative Strength Index (RSI) | 31.88 |
Average Volume (20 Days) | 125.31K |
Income Statement
In the last 12 months, HOOKIPA Pharma had revenue of 20.13M and earned -81.58M in profits. Earnings per share was -8.63.
Revenue | 20.13M |
Gross Profit | 16.58M |
Operating Income | -97.69M |
Net Income | -81.58M |
EBITDA | -77.34M |
EBIT | -97.69M |
Earnings Per Share (EPS) | -8.63 |
Balance Sheet
The company has 117.1M in cash and 6.56M in debt, giving a net cash position of 110.54M.
Cash & Cash Equivalents | 117.1M |
Total Debt | 6.56M |
Net Cash | 110.54M |
Retained Earnings | -369.26M |
Total Assets | 109.73M |
Working Capital | 64.59M |
Cash Flow
In the last 12 months, operating cash flow was -57.52M and capital expenditures -4.16M, giving a free cash flow of -61.68M.
Operating Cash Flow | -57.52M |
Capital Expenditures | -4.16M |
Free Cash Flow | -61.68M |
FCF Per Share | -6.53 |
Margins
Gross margin is 82.35%, with operating and profit margins of -485.34% and -405.29%.
Gross Margin | 82.35% |
Operating Margin | -485.34% |
Pretax Margin | -403.46% |
Profit Margin | -405.29% |
EBITDA Margin | -384.24% |
EBIT Margin | -485.34% |
FCF Margin | -306.44% |
Dividends & Yields
HOOK does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -567.76% |
FCF Yield | -418.93% |
Analyst Forecast
The average price target for HOOK is $4.5, which is 196.1% higher than the current price. The consensus rating is "Hold".
Price Target | $4.5 |
Price Target Difference | 196.1% |
Analyst Consensus | Hold |
Analyst Count | 3 |
Stock Splits
The last stock split was on Jul 10, 2024. It was a backward split with a ratio of 1:10.
Last Split Date | Jul 10, 2024 |
Split Type | backward |
Split Ratio | 1:10 |
Scores
Altman Z-Score | -4.9 |
Piotroski F-Score | 2 |